Short-acting GHRH receptor agonism · Peptide
Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.
Open in the interactive library →Compare with other compounds →
Guide retains a fasted / bedtime CJC no-DAC plus ipamorelin proposal.
Context: Attributed clinic-style example.
Limitations: No validated combination outcome protocol. Long-acting CJC-1295 studies do not establish no-DAC PK.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: CJC no-DAC / Mod GRF(1-29) with ipamorelin
Attributed proposal / anecdote: Amount: Approximately 100 mcg CJC no-DAC + 150–250 mcg ipamorelin; Frequency: Optional five days on / two days off; Timing: Fasted 90–120 minutes after food; commonly pre-bed; optional fasted morning use; Route: SC; Formulation: CJC no-DAC / Mod GRF(1-29) with ipamorelin
Limitations: Retained from the field-guide synthesis; original clinic/source identifier is not supplied. Not a validated clinical combination protocol.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Route: Not documented; Sequence: Add CJC-1295 / ipamorelin after earlier fat-loss phases; substitute tesamorelin for visceral-fat concerns
Limitations: No amount, duration, route, phase interval or CJC DAC status is supplied. Association with this no-DAC listing does not establish that the video used no-DAC.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Amount: 250 mcg each; Frequency: 5 days on and 2 days off; Duration: 10–12 weeks, then 4–6 weeks off; Timing: Bedtime or fasted morning; Route: SC
Limitations: Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.
The cited human CJC-1295 study concerned the long-acting compound.
Context: No-DAC / Mod GRF and DAC are not interchangeable.
Limitations: Do not apply the long-acting study half-life to no-DAC products.
The article’s approximately 30-minute duration and single bedtime pulse must not be presented as verified human SC PK. Long-acting CJC studies cannot establish the proposed blend’s sleep, recovery or body-composition outcomes. The author’s wearable-estimated deep-sleep increase is an individual anecdote; native IV GHRH sleep studies do not validate predictable sleep improvements with this SC blend. Exact food separation and bedtime superiority remain unvalidated.
Context: October 15 2026 article audit; primary evidence and author claims distinguished.
Limitations: No established general treatment protocol; retain the population, molecule and route limitations.
Open this exact record in the library →Suggest a correctionThese compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.